Auckland Uniservices Limited

The Administrators of the Tulane Educational Fund

Fonterra Corporate Research and Development Ltd.

Nzmp + Health and Nutrition Unit

New Zealand Dairy Board

Ian Reginald Reid

Jillian Cornish

Garth James Smith Cooper

David H Coy

Neill Ward Haggarty

Kay Patricia Palmano

Kate Patricia Palmano

Dorit Naot

Garth James Cooper

Jianming Lin

Andrew Bevis Grey

Jill Cornish

A pure lactoferrin polypeptide containing no more than two metal ions per molecule, or a mixture of the polypeptide and a fragment thereof. The polypeptide or the mixture stimulates skeletal growth and inhibits bone resorption. Also disclosed is a method of treating a bone-related disorder with the polypeptide or the mixture.

Lactoferrin

This invention features a method for treating a bone condition in a patient, e.g., a mammal, a human, a horse, a dog, or a cat. The method includes administering an effective amount of FGF-8, FGF-8 analog, or a FGF-8 agonist to the patient.

FGF-8 methods of use

A method for promoting bone growth in a patient (e.g., a mammal such as a human) said method including the step of administering a therapeutically effective amount of adrenomedullin or an adrenomedullin agonist to said patient.

Adrenomedullin agonists

We claim a method of treating a patient to stimulate chondrocyte proliferation comprising administering to said patient an adrenomedullin analog that is adrenomedullin-(27&#x2013;52) wherein said patient is suffering from cartilage disorders, and a method of stimulating chondrocyte proliferation comprising administering to chondrocyte cells adrenomedullin-(27&#x2013;52).

Therapeutic method

LDL receptor-related proteins 1 and 2 (LRP-1 and LRP-2) and interaction between lactoferrin and LRP-1, LRP-2, or p42/44 MAP kinase in diagnosis and treatment of disorders such as bone or cartilage disorders. Also disclosed are methods of screening for related therapeutic compounds.

LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions

The present invention relates to new therapeutic use of amylin as agent which stimulates chondrocyte proliferation and which therefore have utility in the treatment of cartilage disorders and/or cartilage mediated bone growth.

A compound derived from amylin is disclosed. Pharmaceutical compositions contain such compounds and are used in the treatment of bone disorders where stimulation of bone growth is required.

Growing community of inventors

Auckland, New Zealand

Ian Reginald Reid